Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SciClone updates progress of Zadaxin

Feb. 11, 2002

MCA approves phase II study of TTS in pancreatic cancer

Feb. 7, 2002

Fast track designation for Oncophage in metastatic melanoma

Feb. 6, 2002

AltaRex offers further analysis of OvaRex results

Feb. 5, 2002

Preclinical milestone reached for Crucell human anti-CD46 antibody

Feb. 4, 2002

AHP describes preparation of novel soluble pegylated rapamycin derivatives

Feb. 4, 2002

Board recommends continuation of Biomira's phase IIb trial of BLP25 in NSCLC

Jan. 31, 2002

Rituximab + CHOP as a new drug combination for aggressive NHL

Jan. 29, 2002

Phase IIb results reported for OvaRex in metastatic ovarian cancer

Jan. 29, 2002

Patient enrollment completed in trial of G17DT in gastric cancer

Jan. 25, 2002

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...